The Martin Delaney Collaboratories for HIV Cure Research is the flagship NIH program on HIV cure research. The purpose is to foster dynamic, multidisciplinary collaborations between basic, applied, and clinical researchers studying HIV persistence and developing potential curative strategies. This is accomplished by establishing partnerships across academia, industry, government, and community, with a goal of leveraging common resources to accelerate the pace of HIV cure research and engage the next generation of HIV cure researchers.
The program was launched in July 2011 with the funding of three Collaboratories: CARE, DARE, and defeatHIV. In July 2016, the program was expanded to include three additional Collaboratories (BELIEVE, BEAT-HIV, and I4C) for a total of six Collaboratories, supporting a total of approximately 300 researchers. In 2021, the program was further expanded to 10 Collaboratories, with one of them focused specifically on HIV cure research in infants and children.
Main Areas of Focus
- Basic and clinical research to characterize persistent HIV reservoirs and to determine the mechanisms associated with viral latency, post-treatment control, and viral rebound
- Applied research to develop and test therapeutic strategies for eradicating or controlling residual virus using in vitro, ex vivo, and animal models
- Designing clinical trial protocols to test safety, tolerability, and initial proof-of-concept of curative therapies
- Community engagement to advance research literacy, set realistic expectations of success, and address potential concerns regarding acceptability, enrollment, safety, or ethics
Pathogenesis and Basic Research Branch, Basic Sciences Program, Division of AIDS, NIAID oversees the program by convening an MDC Program Management Team made up of representatives from other Branches, Programs, Divisions, and Institutes.
Strategies for an HIV Cure symposia
Grantee institutions: Beth Israel Deaconess Medical Center, Emory University, Gladstone Institutes, Johns Hopkins University, Sanford Burnham Prebys, Temple University, University of California – San Francisco, The University of North Carolina at Chapel Hill, Weill Cornell Medicine, The Wistar Institute.